MedTrace Logo

An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector

NCT06994936 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-12-09

No results posted yet for this study

Summary

This is a study to confirm the relative bioequivalence of sonelokimab administered subcutaneously via a prefilled syringe (PFS) or an autoinjector (AI) in healthy adult volunteers

Conditions

  • Relative Bioequivalence

Interventions

DRUG

Sonelokimab

sonelokimab 120 mg administered subcutaneously via an AI

DRUG

Sonelokimab

sonelokimab 120 mg administered subcutaneously via a PFS

Sponsors & Collaborators

  • MoonLake Immunotherapeutics AG

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-05
Primary Completion
2025-11-01
Completion
2025-11-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06994936 on ClinicalTrials.gov